biotech · Hematological or solid tumor malignancies or autoimmune diseases · Intracerebral Haemorrhage · IPSC
Century Therapeutics
Century Therapeutics is a biotech organization headquartered in Philadelphia, USA. It trades on NYSE under ticker IPSC. Primary therapeutic focus areas include Hematological or solid tumor malignancies or autoimmune dise
Company details
- Status
- Public
- HQ
- Philadelphia, USA
- Founded
- 2018
- Employees
- 104
- Programs
- 10
- Drugs
- 9
- Patents
- 39
CNTY-101-151-01
Phase 1 · other · systemic lupus erythematosus [SLE]/lupus nephritis [LN], idiopathic inflammatory myopathy [IIM], and diffuse cutaneous systemic sclerosis [DcSSc]
CNTY-101-151-01 for systemic lupus erythematosus [SLE]/lupus nephritis [LN], idiopathic inflammatory myopathy [IIM], and diffuse cutaneous systemic sclerosis [DcSSc] is a Phase 1 program (other) at Century Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code CNTY-101-151-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Century Therapeutics
- Phase
- Phase 1
- Modality
- other
- Indication
- systemic lupus erythematosus [SLE]/lupus nephritis [LN], idiopathic inflammatory myopathy [IIM], and diffuse cutaneous systemic sclerosis [DcSSc]
- Status
- active
- Trials
- 1